Company

FDA Approves Bayer's Sunharbo (Asundexian) – World's First FXIa Inhibitor for Secondary Stroke Prevention
BayerETR: BAYN

FDA Approves Bayer’s Sunharbo (Asundexian) – World’s First FXIa Inhibitor for Secondary Stroke Prevention

Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for asundexian 50 mg tablets, under the brand name Sunharbo — the first…

Charles River to Acquire Frontage's Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

Charles River to Acquire Frontage’s Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
MGI Tech's DNBSEQ-E25 Receives NMPA License as World's First Self-Luminescent Sequencer
Genomics / NGSMGI Tech

MGI Tech’s DNBSEQ-E25 Receives NMPA License as World’s First Self-Luminescent Sequencer

Medtronic's BrainSense Technologies Win EU, UK CE Mark for Parkinson's Treatment
MedtronicNYSE: MDT

Medtronic’s BrainSense Technologies Win EU, UK CE Mark for Parkinson’s Treatment

Sansure Biotech to Acquire Sinobioway Hygene for $110M to Boost Product Pipeline
Sansure BiotechSHA: 688289

Sansure Biotech to Acquire Sinobioway Hygene for $110M to Boost Product Pipeline

Novo Nordisk Launches Rybelsus in China, World's First Oral GLP-1RA
DiabetesMarket launch

Novo Nordisk Launches Rybelsus in China, World’s First Oral GLP-1RA

Show More